A children’s vaccine costs a health system a few dollars today and might prevent a hospitalization a decade from now — but the accountant closing this year’s books rarely sees the connection.

The idea that preventive care saves money has been political shorthand for a generation of health reform. It shows up in campaign speeches, insurer marketing, and hospital mission statements. It is also, according to some of the most rigorous economic analysis available, mostly not true — at least not in the way people usually mean it.

The Myth That Prevention Pays for Itself

In a widely cited 2008 analysis published in the New England Journal of Medicine, health economists Joshua T. Cohen, Peter J. Neumann, and Milton C. Weinstein reviewed hundreds of cost-effectiveness studies and found that the large majority of preventive interventions — screenings, medications, lifestyle programs — add more to medical spending than they save, even when they improve health outcomes. A handful of measures, including some childhood immunizations, are genuine exceptions that both save money and save lives. But as a blanket claim, “prevention pays for itself” does not hold up against the data.

That finding unsettles a comfortable narrative, but it doesn’t mean prevention is a bad investment — it means the case for it has to be made on health grounds, not budget grounds. And it raises a harder question: if prevention is worth doing but doesn’t neatly pay for itself in dollars, who is supposed to fund it, and on what timeline?

Why the Money Doesn’t Flow That Way

A 2026 analysis from the Milbank Memorial Fund, a nonpartisan health policy foundation, argues that the deeper problem isn’t clinical evidence — it’s plumbing. Author Justin Frazer identifies three structural mismatches that persist even inside “value-based” payment models built to reward outcomes rather than procedures.

The first is investment-return misalignment: the organization that pays for a prevention program is often not the one that captures the savings. A health system that funds a diabetes-prevention or care-coordination effort may reduce hospitalizations — but insurers, not providers, typically realize most of the financial benefit.

The second is fragmentation. Patients cycle between Medicaid, Medicare Advantage, and commercial insurance, sometimes within the same year. When the payoff from a prevention program is spread across multiple payers, no single one has enough stake in the outcome to justify sustained investment — a textbook collective-action problem.

The third is timing. Preventive interventions typically generate financial returns over three to five years. Health system budgets and provider contracts run on an annual cycle. A program has to survive several budget seasons before its savings become visible on a balance sheet, and in the meantime it looks, on paper, like a cost center.

What the Incentive Experiments Show

Policymakers have spent two decades trying to patch this problem with financial incentives — paying doctors or patients directly for preventive actions like screenings, vaccinations, or weight management. A federally funded evidence review conducted for the Agency for Healthcare Research and Quality found the results underwhelming. Only four of nine studies of provider-directed incentives showed a positive effect, and the review characterized the improvements as “moderate at best” — one program raised immunization rates by 7.1 percent, a real but modest gain.

Consumer-facing incentives fared similarly. They worked reasonably well in the short term for simple, one-time actions, but the review found that in every one of the four studies that tracked results after the incentive ended, the improved behavior reverted to its original level. And among the 47 consumer studies reviewed, only seven calculated whether the incentive was actually cost-effective — of those seven, five found that a similar program without the cash incentive would have been the more efficient use of money.

The takeaway isn’t that incentives are worthless. It’s that paying people or providers to act differently, without fixing the underlying financing structure, tends to produce temporary, expensive fixes rather than durable change.

Rebuilding the Books

A few jurisdictions are trying to rewrite the rules rather than patch around them. Massachusetts has piloted multi-payer initiatives that pool funding across insurers to support housing stability and care coordination — an attempt to solve the fragmentation problem directly by making prevention everyone’s investment rather than any single payer’s gamble. California has gone further on paper, setting a regulatory benchmark that requires payers to direct 15 percent of medical spending to primary care by 2034, up from levels that in many plans today hover in the single digits.

The stakes of getting this right show up in international comparisons. The Commonwealth Fund’s 2021 “Mirror, Mirror” report, ranking health systems across wealthy nations, placed the United States last overall despite the country spending roughly 17 percent of its gross domestic product on healthcare in 2019 — far more than any peer nation. Notably, the U.S. ranked near the top on preventive-care processes, meaning its clinical protocols and screening guidelines are competitive. What drags the overall ranking down is everything downstream of the appointment: affordability, administrative burden, and uneven access that leaves preventive care looking robust on paper for people who can’t easily reach it.

None of this means fee-for-service medicine is being torn out overnight. It means the systems narrowing the gap are the ones treating financing structure — not just clinical will — as the thing that has to change.

Sources: Justin Frazer, “Why Prevention Still Struggles Financially—Even in Value-Based Care,” Milbank Memorial Fund, May 2026 (milbank.org); Joshua T. Cohen, Peter J. Neumann, Milton C. Weinstein, “Does Preventive Care Save Money? Health Economics and the Presidential Candidates,” New England Journal of Medicine, February 2008 (nejm.org); Agency for Healthcare Research and Quality, “Economic Incentives for Preventive Care,” Evidence Report Summary (ncbi.nlm.nih.gov); Eric C. Schneider et al., “Mirror, Mirror 2021: Reflecting Poorly,” The Commonwealth Fund, August 2021 (commonwealthfund.org).